Proposed cut-off values to detect cardiac amyloidosis for serum troponin T and NT-proBNP are 0.035 mcg/L and 332 pg/ml, respectively.2 However, these biomarkers are not 100% specific and can be elevated with other disease states including renal failure and liver failure, which may be the case in AL amyloidosis with multi-organ involvement. Endomyocardial biopsy Endomyocardial

biopsy is the most direct Inhibitors,research,lifescience,medical evidence of amyloid deposition to diagnose cardiac amyloidosis. However, Congo red staining of a screening biopsy (i.e., abdominal subcutaneous fat aspirate or rectal biopsy) with associated clinical cardiac features — along with positive noninvasive test results (ECG, echo, or CMR findings IOX1 price suggestive of cardiac amyloidosis) and evidence of an amyloidogenic disorder based on serum and urine monoclonal immunoglobulin testing — is highly suggestive of cardiac amyloidosis.

Investigators have shown that amyloid Inhibitors,research,lifescience,medical deposition can be uneven,11 as suggested by patchy focal LGE obtained through CMR.7 Hence, multiple endomyocardial biopsies may be needed to confirm the diagnosis in such cases. Direct evidence of amyloid deposition Inhibitors,research,lifescience,medical in organs other than through screening biopsy can be provided by serum amyloid P (SAP) component scintigraphy, however planar SAP scintigraphy is unable to image amyloids in the moving heart.5 Evaluation to Prognosticate An acquired cardiomyopathy secondary to amyloid deposition displaying clinical features consistent with congestive failure is associated with a poor prognosis. The 1- to Inhibitors,research,lifescience,medical 2-year survival with cardiac

amyloidosis is less than 50%.1 Dispenzieri et al. demonstrated that patients with AL amyloidosis stratified by biomarker (troponin T and NT-proBNP) elevation were associated with median survivals of 27, 11, and 4 months, respectively, for stages I, II, and III, with stage 1 showing normal to low levels of both biomarkers, stage Inhibitors,research,lifescience,medical II showing one elevated biomarker, and stage III showing elevation of both biomarkers.2, 12 Detectable cardiac troponin I or T confers on average a median survival of approximately 6 to 8 months.12 Echocardiographic imaging surrogates to further prognosticate are based Cell press on underlying elevated ventricular filling pressures, which accounts for the clinical congestive heart failure. Those patients with cardiac amyloidosis and a restrictive mitral valve inflow pattern (i.e., deceleration time <150 msec with an E/A ratio >2.0, Figure 2) in the presence of impaired relaxation had a 1-year survival less than 50% compared to patients with normal LV filling pressures having a 1-year survival greater than 90%.13 Similarly, those patients with AL amyloidosis showing echo features of left ventricular hypertrophy and symptoms of clinical heart failure have a 6-month survival of only 50%.